What Is the Moderna Vaccine and How Does It Work?

The Moderna vaccine, sold under the brand name Spikevax, is a messenger RNA (mRNA) vaccine designed to teach your cells how to make a harmless piece of the SARS-CoV-2 spike protein so your immune system can learn to recognize and fight the real virus. In the pivotal clinical trial, it showed about 94% efficacy against symptomatic COVID-19 and prevented all cases of severe disease in the vaccinated group. The technology behind it, packaging synthetic mRNA inside tiny fat particles and injecting it into your arm, was the first of its kind to reach widespread use and has since become a platform for vaccines against other diseases.

What mRNA Actually Does Inside Your Body

Every cell in your body already uses mRNA as an intermediary. Your DNA holds the master blueprint; mRNA carries a temporary copy of specific instructions from that blueprint to your cell’s protein-making machinery. The Moderna vaccine takes advantage of this natural process by delivering a synthetic strip of mRNA that encodes the spike protein found on the surface of SARS-CoV-2. Once inside a cell, that synthetic mRNA is read by ribosomes, the same molecular machines that translate your own genetic messages into proteins all day long. The cell produces copies of the spike protein, which then appear on its surface or get released into the surrounding tissue.

A critical design choice makes this work better than it otherwise would. The synthetic mRNA in the Moderna vaccine uses a modified building block called N1-methylpseudouridine in place of one of the standard RNA bases. This swap matters because unmodified synthetic RNA tends to trigger alarm systems inside cells, leading to its rapid destruction before it can be read. The modification essentially lets the mRNA slip past those alarms, increasing the amount of spike protein the cell produces and reducing unwanted inflammatory signaling.¹

The mRNA itself is fragile and short-lived. It does not enter the cell’s nucleus, so it never interacts with your DNA. After the ribosomes have read it a number of times, the cell’s normal cleanup enzymes break it down, typically within a few days. The spike proteins left behind are what do the immunological heavy lifting.

How Lipid Nanoparticles Get mRNA Into Cells

Naked mRNA injected into tissue would be destroyed within minutes by enzymes in the body that chew up stray RNA. To protect the payload and help it get inside cells, Moderna wraps its mRNA in lipid nanoparticles, essentially tiny spheres made of several types of fat molecules, each serving a distinct purpose in terms of the particle’s size, stability, and ability to merge with cell membranes.² These particles are roughly a hundred nanometers across, far too small to see, and they resemble the natural lipid vesicles your own body uses to shuttle materials around.

After injection into the muscle of your upper arm, the lipid nanoparticles are taken up by nearby cells through a process called endocytosis, where the cell membrane wraps around the particle and pulls it inside into a compartment called an endosome. Getting the mRNA out of that endosome and into the cell’s main interior is actually one of the biggest challenges in the whole design. The key ingredient is an ionizable lipid, a fat molecule that changes its electrical charge when the environment turns acidic. As the endosome naturally becomes more acidic, the ionizable lipid picks up a positive charge, which disrupts the endosomal membrane and lets the mRNA escape into the cell’s cytoplasm, where it can finally be read by ribosomes.³⁴

This endosomal escape step is far from perfectly efficient; most of the mRNA that enters a cell never makes it out of the endosome. Researchers have spent considerable effort optimizing the internal structure of the lipid particles to improve that escape rate, and much of the difference between early mRNA vaccine prototypes and the version that reached clinics came down to better lipid formulations rather than changes to the mRNA itself.

How Your Immune System Learns From the Spike Protein

Once cells in and around the injection site start displaying spike protein on their surfaces, the immune system treats them much as it would cells infected by a real virus. The spike protein fragments are presented on cell-surface molecules that act like display cases, alerting passing immune cells that something foreign is present.⁵ This kicks off two main arms of the immune response: antibody production and T-cell activation.

On the antibody side, the vaccine triggers a strong germinal center reaction in nearby lymph nodes. Germinal centers are specialized zones where B cells undergo a competitive selection process, refining their antibodies to bind the spike protein more and more tightly. In studies of vaccinated people, researchers found that a single dose of mRNA vaccine was enough to generate potent germinal center B cell and helper T cell responses, along with long-lived plasma cells and memory B cells.⁶ A landmark study published in Nature went further, examining lymph node tissue directly: spike-binding germinal center B cells were found at high levels for at least 12 weeks after the booster dose, demonstrating a persistent immune training process rather than a brief, one-off reaction.⁷

The T-cell arm is just as important, though it gets less public attention. Studies of both younger and older adults showed that two doses of mRNA vaccine significantly increased spike-specific CD4+ and CD8+ T cells, and a third dose boosted those numbers further still.⁸ CD4+ T cells help coordinate the broader immune response, while CD8+ T cells can directly kill infected cells. Research comparing adults and children found that mRNA vaccination without prior infection generated a strong interferon-gamma response, associated with antiviral defense, in both age groups, though the killer T cell response was more pronounced in adults.⁹

What the Clinical Trials Showed

The original phase 3 COVE trial enrolled about 30,000 participants and randomized them to receive either two doses of the Moderna vaccine (mRNA-1273) or a placebo. The results were striking: symptomatic COVID-19 was confirmed in 185 people in the placebo group compared to just 11 in the vaccinated group, translating to an efficacy of 94.1%. All 30 cases of severe COVID-19, including one death, occurred in the placebo group.¹⁰ A follow-up analysis during the blinded phase of the same trial confirmed 93.2% efficacy against symptomatic infection even as new variants began circulating.¹¹

Head-to-head comparisons with the Pfizer-BioNTech vaccine (BNT162b2) also emerged. One study measuring antibody levels found that Moderna recipients had higher levels of spike-targeting IgG antibodies both before and after a booster dose compared to Pfizer recipients. Before the boost, Moderna recipients averaged about 19 micrograms per milliliter versus roughly 6 for Pfizer recipients; after the boost, the gap narrowed but persisted at about 69 versus 46.¹² The difference likely reflects Moderna’s higher mRNA dose (100 micrograms versus 30 in the Pfizer primary series) and the slightly longer interval between its two doses.

Common Side Effects and Why They Happen

Most people who received the Moderna vaccine experienced some combination of injection-site pain, fatigue, headache, muscle aches, and sometimes fever, particularly after the second dose. These reactions tended to peak within 24 to 48 hours and resolved within a few days. They were generally more pronounced than what people reported after the first dose, which tracks with the fact that the immune system was already primed and responded more aggressively to the second exposure.

Research suggests that the intensity of side effects after the initial vaccine series is linked to a strong innate immune response, the body’s first-line defense system that kicks in before the more targeted adaptive response develops. Interestingly, side effects after booster doses appeared to decrease compared to the original series, which may reflect a reduced innate immune reaction with repeated exposure even as adaptive immunity continues to strengthen.¹³ In practical terms, that means later boosters are typically easier to tolerate than the original two-dose series.

Myocarditis Risk in Young Males

The most closely watched rare side effect of mRNA COVID-19 vaccines has been myocarditis, an inflammation of the heart muscle. Population-level surveillance established that the highest risk occurs in males aged roughly 12 to 30, typically within one to two weeks after the second dose of the primary series.¹⁴ Large European studies estimated between about 1.3 and 1.9 excess cases per 10,000 young male Spikevax recipients after the second dose, higher than rates seen with the Pfizer vaccine in the same age group.

A Canadian study looking specifically at males aged 18 to 29 found that the risk of myocarditis or pericarditis after a second Moderna dose was roughly five to six times higher than after a second Pfizer dose.¹⁵ A systematic review reported incidence rates after the second Moderna dose in men under 40 ranging from about 2.4 to 30 cases per 100,000 persons or doses, depending on the study and methodology used.¹⁶ Most cases were mild and resolved with standard supportive care. The difference in myocarditis rates between the two mRNA vaccines is widely attributed to Moderna’s higher mRNA dose, and it led several countries to preferentially recommend the Pfizer vaccine for younger males or to reduce the Moderna dose for boosters.

How Long Does Protection Last

Antibody levels after vaccination follow a predictable pattern: they peak a few weeks after the second dose, then gradually decline over the following months. But antibodies are only one layer of immune memory. A study tracking vaccinated individuals over six months found that while circulating antibodies fell from their peak, functional memory B cells actually increased between three and six months post-vaccination, and the majority of those cells could recognize several variants of concern, including Alpha, Beta, and Delta. Early CD4+ T cell responses correlated with longer-lasting antibody protection, suggesting the different arms of the immune system reinforce each other.¹⁷

With repeated booster doses, the immune system continues to mature its response. Research has shown that after multiple vaccinations, some people develop a class of antibody called IgG4 in addition to the IgG1 and IgG3 types that dominate earlier responses. This class switch appears to reflect ongoing germinal center activity and continued affinity maturation, where B cells keep refining their antibodies to bind the spike protein more precisely.¹⁸ The practical upshot is that while you may need periodic boosters to maintain high circulating antibody levels, your immune memory deepens with each exposure.

Updated Formulations for New Variants

One of the advantages of the mRNA platform is speed of adaptation. Because the vaccine is essentially a set of genetic instructions, updating it to match a new variant means swapping in the new spike protein sequence and running the same manufacturing process. Moderna has used this capability to produce updated boosters as SARS-CoV-2 has evolved.

The first major update was a bivalent booster combining the original Wuhan-Hu-1 spike sequence with the Omicron BA.1 sequence, each at 25 micrograms for a total 50-microgram dose. This formulation, tested in a phase 2-3 trial against the original booster, was designed to broaden the immune response against the dramatically different Omicron lineage.¹⁹ Since then, Moderna has moved to monovalent formulations targeting whichever variant is dominant at the time, following a model similar to annual flu vaccine updates. The FDA now reviews and authorizes updated COVID-19 vaccine compositions each year based on the circulating strains.

Protecting Newborns Through Maternal Vaccination

Infants are too young for COVID-19 vaccination in their first months of life, which creates a vulnerability gap. Research on pregnant and breastfeeding individuals has shown that mRNA vaccination generates antibodies that cross the placenta and also appear in breast milk. A study of maternal vaccination found that booster doses significantly increased spike-specific IgG levels in both maternal plasma and breast milk, and that these antibodies were detectable in cord blood and newborn blood, confirming passive transfer to the baby both before and after birth.²⁰ The antibody levels in the newborn were lower than in the mother’s circulation, but the finding underscores that maternal vaccination during pregnancy can provide a bridge of protection for newborns until they become eligible for their own shots.

Cold Chain and Storage Constraints

Because mRNA is inherently fragile, the vaccine must be kept cold throughout its journey from factory to arm. Strict cold-temperature storage is mandatory to preserve the mRNA’s stability and the integrity of the lipid nanoparticles.²¹ The original formulation required storage at around minus 20 degrees Celsius for long-term preservation, though it could be kept in a standard refrigerator for up to 30 days before use. This was less demanding than the Pfizer vaccine’s initial requirement of ultra-cold storage at minus 70 degrees, which made the Moderna vaccine somewhat easier to distribute in settings without specialized freezers.

Manufacturing the vaccine is also a complex, multi-step process. Production starts with an in vitro transcription reaction, where enzymes read a DNA template and produce the mRNA strands. That reaction is followed by extensive purification, including steps to remove the DNA template, leftover enzymes, and incomplete RNA fragments. The purified mRNA is then encapsulated in lipid nanoparticles, and the final product undergoes quality testing before being filled into vials and shipped under cold-chain conditions. Scaling up this process to produce billions of doses was one of the major logistical challenges of the pandemic response.

The mRNA Platform Beyond COVID-19

The success of the Moderna COVID-19 vaccine proved that mRNA technology could work at scale, and the same platform is now being applied to other diseases. In 2024, the FDA approved Moderna’s mRNA vaccine against respiratory syncytial virus (RSV), a significant cause of hospitalization in older adults and young children, marking the first non-COVID mRNA vaccine to reach the market.²²

The pipeline extends well beyond respiratory viruses. Clinical trials are underway for mRNA vaccine candidates targeting HIV, cytomegalovirus (CMV), and rabies, among others. Perhaps most intriguingly, the platform has expanded into oncology: personalized mRNA vaccines that encode unique mutations found in an individual patient’s tumor are being tested for melanoma and other cancers.²³ In the cancer application, the idea is to train the immune system to recognize and attack cells carrying those specific mutations, turning the same basic mechanism of the COVID-19 vaccine into a therapeutic tool rather than a purely preventive one. These programs are still in early stages, but they illustrate how a technology that was largely theoretical before 2020 has become one of the most active areas of vaccine and drug development.